Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: carmoisine; gelatin; sodium stearylfumarate; titanium dioxide; brilliant blue fcf; colloidal anhydrous silica; pregelatinised maize starch; maltodextrin; crospovidone; brilliant black bn; patent blue v; erythrosine - pomalidomide medicianz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medicianz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: titanium dioxide; gelatin; colloidal anhydrous silica; sodium stearylfumarate; carmoisine; brilliant blue fcf; pregelatinised maize starch; maltodextrin; crospovidone; brilliant black bn; patent blue v; erythrosine - pomalidomide medsurge, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medsurge, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 2 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; crospovidone; sunset yellow fcf; gelatin; brilliant black bn; titanium dioxide; sodium stearylfumarate; colloidal anhydrous silica; maltodextrin; patent blue v; carmoisine - pomalidomide medicianz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medicianz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 2 mg - capsule, hard - excipient ingredients: crospovidone; gelatin; pregelatinised maize starch; brilliant black bn; patent blue v; maltodextrin; titanium dioxide; sunset yellow fcf; colloidal anhydrous silica; carmoisine; sodium stearylfumarate - pomalidomide medsurge, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medsurge, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: crospovidone; maltodextrin; carmoisine; sodium stearylfumarate; gelatin; pregelatinised maize starch; patent blue v; colloidal anhydrous silica; brilliant blue fcf; titanium dioxide; iron oxide yellow; brilliant black bn; iron oxide black - pomalidomide medicianz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medicianz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: crospovidone; colloidal anhydrous silica; iron oxide yellow; maltodextrin; brilliant blue fcf; gelatin; pregelatinised maize starch; titanium dioxide; patent blue v; carmoisine; brilliant black bn; iron oxide black; sodium stearylfumarate - pomalidomide medsurge, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medsurge, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Kanada - angličtina - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 1mg - pomalidomide 1mg

Kanada - angličtina - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 2mg - pomalidomide 2mg

Kanada - angličtina - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 4mg - pomalidomide 4mg